In addition to addressing the limitations detailed above, future research may also benefit from incorporating biofluid measures of GFAP, a measure of astrocytic reactivity, and VEGF, which has been linked to rTMS efficacy in clinical trials for depression (Fukuda et al., 2020; Elemery et al., 2022). The gene discussed is GFAP; the disease is major depressive disorder.